According to a small study by Weill Cornell Medicine and New York-Presbyterian investigators, vaccinating mothers using Pfizer Inc’s (NYSE:PFE) vaccine against respiratory syncytial virus (RSV) during late pregnancy to protect their newborns is not associated with an increased risk of preterm birth or other poor outcomes. The FDA approved the Abrysvo (RSVpreF) vaccine last year. It targets women in their second or third trimesters to prevent RSV infections in newborns during their first six months. Also Read: UK Chooses Pfizer Over GSK for Multi-Million Dose RSV Vaccine Contract. In September 2023, the U.S. Centers for Disease Control and ...